Delta-Fly Pharmaの株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2021/03/31 | 1,330 | 1,431 | 1,302 | 1,385 | +63 | +4.8% | 321,800 |
2021/03/30 | 1,294 | 1,343 | 1,272 | 1,322 | +44 | +3.4% | 219,100 |
2021/03/29 | 1,368 | 1,370 | 1,256 | 1,278 | -72 | -5.3% | 384,100 |
2021/03/26 | 1,264 | 1,358 | 1,263 | 1,350 | +86 | +6.8% | 261,400 |
2021/03/25 | 1,380 | 1,380 | 1,260 | 1,264 | -122 | -8.8% | 434,100 |
2021/03/24 | 1,327 | 1,407 | 1,288 | 1,386 | +29 | +2.1% | 407,300 |
2021/03/23 | 1,410 | 1,430 | 1,345 | 1,357 | -39 | -2.8% | 287,300 |
2021/03/22 | 1,385 | 1,448 | 1,360 | 1,396 | +25 | +1.8% | 398,900 |
2021/03/19 | 1,251 | 1,385 | 1,242 | 1,371 | +111 | +8.8% | 333,900 |
2021/03/18 | 1,310 | 1,335 | 1,236 | 1,260 | -13 | -1% | 257,400 |
2021/03/17 | 1,235 | 1,312 | 1,210 | 1,273 | +24 | +1.9% | 331,900 |
2021/03/16 | 1,146 | 1,254 | 1,135 | 1,249 | +104 | +9.1% | 165,900 |
2021/03/15 | 1,130 | 1,149 | 1,120 | 1,145 | +21 | +1.9% | 53,300 |
2021/03/12 | 1,116 | 1,125 | 1,096 | 1,124 | +18 | +1.6% | 52,800 |
2021/03/11 | 1,100 | 1,111 | 1,073 | 1,106 | +16 | +1.5% | 40,700 |
2021/03/10 | 1,070 | 1,100 | 1,070 | 1,090 | +20 | +1.9% | 65,300 |
2021/03/09 | 1,054 | 1,078 | 1,026 | 1,070 | +22 | +2.1% | 69,500 |
2021/03/08 | 1,082 | 1,102 | 1,040 | 1,048 | -19 | -1.8% | 86,300 |
2021/03/05 | 1,090 | 1,099 | 1,012 | 1,067 | -36 | -3.3% | 186,800 |
2021/03/04 | 1,138 | 1,151 | 1,087 | 1,103 | -35 | -3.1% | 112,400 |
2021/03/03 | 1,151 | 1,157 | 1,132 | 1,138 | -3 | -0.3% | 44,300 |
2021/03/02 | 1,179 | 1,195 | 1,126 | 1,141 | -24 | -2.1% | 92,300 |
2021/03/01 | 1,169 | 1,183 | 1,137 | 1,165 | +12 | +1% | 99,400 |
2021/02/26 | 1,132 | 1,175 | 1,105 | 1,153 | +13 | +1.1% | 108,100 |
2021/02/25 | 1,143 | 1,154 | 1,117 | 1,140 | +27 | +2.4% | 47,900 |
2021/02/24 | 1,155 | 1,175 | 1,113 | 1,113 | -52 | -4.5% | 75,700 |
2021/02/22 | 1,110 | 1,172 | 1,103 | 1,165 | +51 | +4.6% | 71,200 |
2021/02/19 | 1,126 | 1,134 | 1,081 | 1,114 | -12 | -1.1% | 66,200 |
2021/02/18 | 1,158 | 1,166 | 1,123 | 1,126 | -27 | -2.3% | 56,900 |
2021/02/17 | 1,110 | 1,157 | 1,110 | 1,153 | +33 | +2.9% | 60,500 |
2021/02/16 | 1,100 | 1,134 | 1,090 | 1,120 | +16 | +1.4% | 77,800 |
2021/02/15 | 1,110 | 1,116 | 1,060 | 1,104 | ±0 | ±0% | 117,500 |
2021/02/12 | 1,120 | 1,123 | 1,090 | 1,104 | -25 | -2.2% | 97,900 |
2021/02/10 | 1,127 | 1,138 | 1,115 | 1,129 | -18 | -1.6% | 95,400 |
2021/02/09 | 1,180 | 1,209 | 1,135 | 1,147 | -3 | -0.3% | 273,000 |
2021/02/08 | 1,181 | 1,181 | 1,130 | 1,150 | -32 | -2.7% | 108,500 |
2021/02/05 | 1,165 | 1,184 | 1,141 | 1,182 | +16 | +1.4% | 93,500 |
2021/02/04 | 1,150 | 1,168 | 1,126 | 1,166 | +22 | +1.9% | 78,300 |
2021/02/03 | 1,140 | 1,160 | 1,112 | 1,144 | +16 | +1.4% | 87,700 |
2021/02/02 | 1,108 | 1,134 | 1,076 | 1,128 | +30 | +2.7% | 88,800 |
2021/02/01 | 1,103 | 1,108 | 1,057 | 1,098 | -21 | -1.9% | 108,600 |
2021/01/29 | 1,163 | 1,177 | 1,104 | 1,119 | -41 | -3.5% | 169,700 |
2021/01/28 | 1,162 | 1,185 | 1,149 | 1,160 | -32 | -2.7% | 90,000 |
2021/01/27 | 1,211 | 1,254 | 1,180 | 1,192 | -19 | -1.6% | 110,500 |
2021/01/26 | 1,242 | 1,253 | 1,206 | 1,211 | -30 | -2.4% | 67,500 |
2021/01/25 | 1,240 | 1,249 | 1,214 | 1,241 | +1 | +0.1% | 72,100 |
2021/01/22 | 1,236 | 1,260 | 1,207 | 1,240 | -7 | -0.6% | 86,000 |
2021/01/21 | 1,245 | 1,250 | 1,202 | 1,247 | -6 | -0.5% | 113,800 |
2021/01/20 | 1,222 | 1,260 | 1,220 | 1,253 | +31 | +2.5% | 89,200 |
2021/01/19 | 1,218 | 1,228 | 1,199 | 1,222 | +2 | +0.2% | 90,900 |
1001~
1050
件表示中 / 1598件
類似銘柄と比較する
現在ご覧いただいている「DELTA-P」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
DELTA-P | 45,600円 | - | - | 0.00% | - | 14.13倍 |
|
創薬ベンチャー。既存の抗がん物質を組み合わせて安全性と有効性を高めた抗がん剤を開発 |
カルナバイオ | 28,000円 | +13.5% | - | 0.00% | - | 2.16倍 |
|
キナーゼタンパク質の販売や受託試験など創薬初期の支援事業が柱。キナーゼ阻害剤で創薬も |
DWTI | 10,200円 | -15.1% | - | 0.00% | - | 6.31倍 |
|
三重大学発創薬ベンチャー。プロテインキナーゼ阻害剤開発技術はじめ眼病治療薬開発に集中 |
免疫生物 | 47,400円 | +13.4% | +44.0% | 0.00% | 20.54倍 | 3.30倍 |
|
研究用試薬の製販・受託。遺伝子組み換えカイコの基礎研究は休止し、化粧品等応用開発に移行 |
VIS | 67,300円 | +306.2% | - | 0.00% | 25.98倍 | 1.98倍 |
|
mRNA標的低分子創薬技術を製薬会社に提供。共同創薬研究などによる契約金収入が柱 |
市場注目の銘柄
チャート関連のコラム